A minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma using biomarkers in duodenal juice

Pancreas

Volumn 42, Issue 2, 2013, Pages 187-192

  Mori, Yasuhisa ^a   Ohtsuka, Takao ^a   Kono, Hiroshi ^a   Nagayoshi, Yosuke ^a   Ideno, Noboru ^a   Aso, Teppei ^a   Kozono, Shingo ^a   Ohuchida, Kenoki ^a   Takahata, Shunichi ^a   Nakamura, Masafumi ^a   Mizumoto, Kazuhiro ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

carcinoembryonic antigen (CEA); duodenal juice; pancreatic ductal adenocarcinoma; pancreatic juice; S100 calcium binding protein P (S100P)

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; INTERLEUKIN 8; PROTEIN S 100; SECRETIN;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CLINICAL ARTICLE; DUODENUM FLUID; ENDOSCOPE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; MALE; MINIMALLY INVASIVE PROCEDURE; PANCREAS ADENOCARCINOMA; PANCREAS JUICE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM-BINDING PROTEINS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DUODENUM; FEMALE; HUMANS; INTERLEUKIN-8; INTESTINAL SECRETIONS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; ROC CURVE; SECRETIN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874080761     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182649979     Document Type: Article

References (33)

1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-465.
2. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: A review of recent advances. Expert Opin Investig Drugs. 2006;15:1395-1410.
3. Goodale RL, Gajl-Peczalska K, Dressel T, et al. Cytologic studies for the diagnosis of pancreatic cancer. Cancer. 1981;47:1652-1655.
4. Nakaizumi A, Tatsuta M, Uehara H, et al. Cytologic examination of pure pancreatic juice in the diagnosis of pancreatic carcinoma. The endoscopic retrograde intraductal catheter aspiration cytologic technique. Cancer. 1992;70:2610-2614.
5. Nakaizumi A, Tatsuta M, Uehara H, et al. Usefulness of simple endoscopic aspiration cytology of pancreatic juice for diagnosis of early pancreatic neoplasm. A prospective study. Dig Dis Sci. 1997;42:1796-1803.
6. Mitchell ML, Carney CN. Cytologic criteria for the diagnosis of pancreatic carcinoma. Am J Clin Pathol. 1985;83:171-176.
7. Kameya S, Kuno N, Kasugai T. The diagnosis of pancreatic cancer by pancreatic juice cytology. Acta Cytol. 1981;25:354-360.
8. Donnellan F, Byrne MF. Prevention of Post-ERCP Pancreatitis. Gastroenterol Res Pract. 2012; doi: 10.1155/2012/796751.
9. Kostrzewska M, Baniukiewicz A, Wroblewski E, et al. Complications of endoscopic retrograde cholangiopancreatography (ERCP) and their risk factors. Adv Med Sci. 2011;56:6-12.
10. Nakaizumi A, Uehara H, Takenaka A, et al. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy. Hepatogastroenterology. 1999;46:31-37.
11. Rolny P, Elwing H, Nilsson LA. The CEA concentration in duodenal fluid in patients with pancreatic disease. Scand J Gastroenterol. 1977;12:759-763.
12. Carr-Locke DL. Serum and pancreatic juice carcinoembryonic antigen in pancreatic and biliary disease. Gut. 1980;21: 656-661.
13. Futakawa N, Kimura W, Yamagata S, et al. Significance of K-ras mutation and CEA level in pancreatic juice in the diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg. 2000;7:63-71.
14. Iguchi H, Sugano K, Fukayama N, et al. Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology. 1996;110:221-226.
15. Watanabe H, Ha A, Hu YX, et al. K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma. Cancer. 1999;86:1441-1448.
16. Japan Pancreas Society. Classification of Pancreatic Carcinoma. nd ed [revised in English]. Tokyo, Japan: Kanehara; 2002.
17. Ohuchida K, Mizumoto K, Egami T, et al. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res. 2006;12:5411-5416.
18. Noh KW, Pungpapong S,Wallace MB, et al. Do cytokine concentrations in pancreatic juice predict the presence of pancreatic diseases? Clin Gastroenterol Hepatol. 2006;4:782-789.
19. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc. 1991;37:383-393.
20. Dominguez Munoz JE. Diagnosis of chronic pancreatitis: functional testing. Best Pract Res Clin Gastroenterol. 2010;24:233-241.
21. Conwell DL, Zuccaro G, Purich E, et al. Comparison of endoscopic ultrasound chronic pancre4titis criteria to the endoscopic secretin-stimulated pancreatic function test. Dig Dis Sci. 2007;52: 1206-1210.
22. Farini R, Nitti D, Del Favero G, et al. CEA concentration and cytology in duodenal fluid collected during the secretin-pancreozymin test. Attempt at an early diagnosis of pancreatic carcinoma by means of simple procedure. Hepatogastroenterology. 1980;27:213-216.
23. Raimondo M, Imoto M, DiMagno EP. Rapid endoscopic secretin stimulation test and discrimination of chronic pancreatitis and pancreatic cancer from disease controls. Clin Gastroenterol Hepatol. 2003;1:397-403.
24. Yamauchi T, Funakoshi A, Kimura T, et al. Clinical studies on CEA of duodenal juice in pancreatic cancer [in Japanese, author's translation]. Nihon Shokakibyo Gakkai Zasshi. 1980;77:949-953.
25. Kawanishi H, Sell JE, Pollard HM. Combined endoscopic pancreatic fluid collection and retrograde pancreatography in the diagnosis of pancreatic cancer and chronic pancreatitis. Gastrointest Endosc. 1975;22:82-85.
26. Sato N, Fukushima N, Maitra A, et al. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol. 2004;164:903-914.
27. Nakata K, Nagai E, Ohuchida K, et al. S100P is a novel marker to identify intraductal papillary mucinous neoplasms. Hum Pathol. 2010;41:824-831.
28. Schor AP, Carvalho FM, Kemp C, et al. S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast. Oncol Rep. 2006;15:3-6.
29. Bartling B, Rehbein G, Schmitt WD, et al. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: Impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer. 2007;43:1935-1943.
30. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166:81-92.
31. Hata S, Sakamoto Y, Yamamoto Y, et al. Prognostic impact of postoperative serum CA19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2012;19:636-641.
32. Kang CM, Kim JY, Choi GH, et al. The use of adjusted preoperative CA19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007;140:31-35.
33. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001;12:375-391.